|
US12435090B2
(en)
|
2021-10-04 |
2025-10-07 |
Repare Therapeutics Inc. |
Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
|
|
KR20250033301A
(ko)
|
2022-07-12 |
2025-03-07 |
위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 |
Myt1 억제제로서의 화합물
|
|
JP2025542085A
(ja)
*
|
2022-11-08 |
2025-12-25 |
ゼノ マネジメント，インコーポレイテッド |
Ｗｅｅ１阻害剤を用いたがん治療のための予測バイオマーカーとしてのサイクリンｅ１状態の使用
|
|
WO2024104282A1
(zh)
*
|
2022-11-14 |
2024-05-23 |
捷思英达控股有限公司 |
一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
|
|
JP2025538617A
(ja)
*
|
2022-11-25 |
2025-11-28 |
上海齊魯制藥研究中心有限公司 |
Ｐｋｍｙｔ１阻害剤、製造方法、医薬組成物及びその使用
|
|
WO2024130425A1
(en)
*
|
2022-12-22 |
2024-06-27 |
Repare Therapeutics Inc. |
Methods of making 2-amino-l-(3-hydroxy-2,6-dimethylphenyl)-5,6- dimethyl-lh-pyrrolo-[2,3-b]pyridine-3-carboxamide, a mytl inhibitor
|
|
WO2024153249A1
(zh)
*
|
2023-01-20 |
2024-07-25 |
杭州英创医药科技有限公司 |
作为pkmyt1抑制剂的化合物
|
|
WO2024160683A1
(en)
*
|
2023-01-30 |
2024-08-08 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Pou5f1b inhibitors
|
|
EP4673436A1
(en)
*
|
2023-02-28 |
2026-01-07 |
F. Hoffmann-La Roche AG |
Indazole compounds as pkmyt1 kinase inhibitors
|
|
AU2024231943A1
(en)
*
|
2023-03-09 |
2025-10-16 |
Cancer Research Technology Limited |
Biarylamide derivatives and their use as pkmyt1 inhibitors
|
|
WO2024235106A1
(zh)
*
|
2023-05-12 |
2024-11-21 |
智擎生技制药股份有限公司 |
稠合吡咯环或稠合吡啶环的化合物
|
|
CN121358735A
(zh)
*
|
2023-07-04 |
2026-01-16 |
杭州领业医药科技有限公司 |
Rp-6306的晶型及其制备方法和用途
|
|
WO2025040014A1
(zh)
*
|
2023-08-18 |
2025-02-27 |
英矽智能科技知识产权有限公司 |
并环化合物及其制备方法和用途
|
|
WO2025056747A1
(en)
*
|
2023-09-14 |
2025-03-20 |
Debiopharm International S.A. |
Combination of a wee1 inhibitor and a pkmyt1 inhibitor
|
|
CN121889394A
(zh)
*
|
2023-09-18 |
2026-04-17 |
英矽智能科技(上海)有限公司 |
作为pkmyt1抑制剂的新型化合物及其用途
|
|
WO2025074271A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Repare Therapeutics Inc. |
Myt1 inhibitors for the treatment of cancers harboring replication stress mutations
|
|
WO2025074275A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Repare Therapeutics, Inc. |
Combination therapies including myt1 inhibitors and wee1 inhibitors
|
|
WO2025106635A1
(en)
*
|
2023-11-15 |
2025-05-22 |
Zeno Management, Inc. |
Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors
|
|
WO2025121807A1
(ko)
*
|
2023-12-08 |
2025-06-12 |
인제대학교 산학협력단 |
Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
|
|
WO2025182927A1
(ja)
*
|
2024-02-27 |
2025-09-04 |
中外製薬株式会社 |
Ｍｙｔ１阻害剤の用途
|
|
WO2025188680A1
(en)
*
|
2024-03-04 |
2025-09-12 |
Cardiff Oncology, Inc. |
Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma
|
|
WO2025237957A1
(en)
*
|
2024-05-14 |
2025-11-20 |
Institut Curie |
Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
|
|
EP4686475A1
(en)
|
2024-07-31 |
2026-02-04 |
Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud |
Xpg inhibitors for use in the treatment of cancer
|